Hepatocellular carcinoma (HCC) has become a leading cause of cancer-related death,
making the elucidation of its underlying mechanisms an urgent priority. Inflammation is an …

Primary liver cancer, mostly hepatocellular carcinoma, remains a difficult-to-treat cancer.
Incidence of liver cancer varies geographically and parallels with the geographic prevalence …

Background For patients with advanced hepatocellular carcinoma, sorafenib is the only
approved drug worldwide, and outcomes remain poor. We aimed to assess the safety and …

Long noncoding RNAs play a pivotal role in T-helper cell development but little is known
about their roles in Treg differentiation and functions during the progression of …

Immunogenic cell death (ICD) can engage a specific immune response and establish a long-
term immunity in hepatocellular carcinoma (HCC). Herein, we design and synthesize a …

Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with
limited therapeutic options. HCC‐induced immunosuppression often leads to ineffectiveness …

Background & Aims Ceramide, a sphingolipid metabolite, affects T-cell signaling, induces
apoptosis of cancer cells, and slows tumor growth in mice. However, it has not been used as …

The recent approval of two immune checkpoint inhibitors for the treatment of malignant
melanoma has sparked great interest by physicians and basic scientists searching for novel …

Background Minimally invasive radiofrequency ablation (RFA) is used as a first-line
treatment option for hepatocellular cancer (HCC) with the weaknesses of incomplete …

Dihydroartemisinin (DHA), a semi-synthetic derivative of artemisinin isolated from the
traditional Chinese herb Artemisia annua L., has been shown to exhibit inhibitory effects on …